Norovirus GII.4 Major Capsid Protein (VP1) (VP1)

The Norovirus GII.4 Major Capsid Protein (VP1) is the primary structural component of the norovirus virion, which is the leading cause of acute viral gastroenteritis worldwide (Source: NIH). VP1 is responsible for forming the viral capsid, facilitating host cell attachment through interactions with histo-blood group antigens (HBGAs), and mediating viral entry (Source: Baylor College of Medicine). It is the principal target for the host's humoral and cellular immune responses, specifically eliciting the production of VP1-specific B-cell receptors (antibodies) and T-cell receptors (Source: ASM). Due to its critical role in infection and its high immunogenicity, VP1 is the primary target for norovirus vaccine development, including virus-like particle (VLP) and DNA-based vaccines (Source: FDA). A significant challenge in targeting VP1 is the rapid antigenic drift of the GII.4 genotype, where mutations in the surface-exposed P2 subdomain lead to the emergence of new variants that can escape existing immunity (Source: PubMed). Consequently, therapeutic strategies often focus on identifying conserved epitopes within VP1 to develop broadly protective vaccines or monoclonal antibodies. Current drug development efforts include bivalent VLP vaccines like HIL-214 and mRNA-based platforms that aim to induce neutralizing antibodies capable of blocking the VP1-HBGA interaction (Source: Moderna).

Other names

Norovirus GII.4 VP1Major capsid proteinORF2 proteinGII.4 capsid proteinNorovirus GII.4 VP1-specific B-cell and T-cell receptors

Neutralization of viral particles and blockade of histo-blood group antigen (HBGA) binding sites to prevent host cell attachment and entry.